IPO Allocation Quid Pro Quo and Analysts' MNPI
You are a portfolio manager at a €600 million European equity fund. A broker's syndicate desk offers you 200,000 shares in the hot IPO of a software company at €18.00 per share. The IPO is 12 times covered. The desk says the allocation is 'a thank-you' for the €1.4 million of commissions your fund generated last year and asks you to direct at least 30% of your secondary-market commissions to its affiliate venue next quarter. The shares would be 0.6% of fund NAV at offer price, within your 5% limit. Separately, the broker's research analyst tells you that the software company's CFO privately said in a roadshow meeting that Q3 bookings are 'well ahead of plan', and the analyst's note raises its revenue forecast before any public announcement. The note is marked 'not for redistribution'. Your fund already holds 3.1% of a competitor, and the IPO would be the fund's first position in the sector. The compliance manual requires pre-clearance for IPOs and prohibits accepting inducements that could conflict with best execution.
1. Identify the regulatory and ethical issues in the IPO allocation and the analyst's information, and explain what you must not do.
Read the worked answer
The allocation is conditional on directing 30% of secondary commissions to the broker's affiliate. That is a quid pro quo: an inducement that could compromise best execution and client interests. It may also be 'spinning' - allocating hot IPO shares in return for order flow - which is a serious conflicts breach. The fund must not accept the allocation on those terms, must not direct orders as payment, and must document the approach. The analyst's information is different: a CFO's private statement that Q3 bookings are 'well ahead of plan' is likely material non-public information. The note is based on it, and 'not for redistribution' does not cure the problem. The fund must not trade the issuer or any related security (including possibly the competitor) on that information, must not circulate the note, and should escalate to compliance immediately.
2. Draft the steps you would take in the next 24 hours, including communications with the syndicate desk, research analyst and compliance.
Read the worked answer
Next 24 hours: (1) tell the syndicate desk orally and in writing that the fund cannot accept an allocation conditioned on commission direction; ask for a clean allocation decision based on merit or decline it. (2) Do not place any order in the IPO, the issuer or the competitor until compliance clears. (3) Send the analyst's note and the CFO statement to compliance; ask whether the fund has been wall-crossed and whether a restricted list is needed. (4) Do not forward the note or discuss the CFO statement with colleagues. (5) Ask compliance to review the broker relationship and whether the approach is reportable. (6) Document times, attendees and exact words. (7) If the fund already holds the competitor, assess whether the information is material to that position; do not trade until cleared.
3. The CIO wants to keep the broker relationship because of research quality. How should the firm manage the conflict and evidence best execution?
Read the worked answer
Keep the broker relationship only if it is managed on merit. Research quality can be assessed, but it must not be paid for with directed order flow or linked to IPO allocations. Under MiFID II, research should be unbundled or paid from a research payment account with client disclosure; dealing commissions should not be used as a reward for allocation. Best execution must be evidenced by venue and execution-quality data, not by the syndicate desk's request. The firm should separate allocation decisions from commission decisions, maintain a gifts/inducements register, disclose conflicts to clients, and have compliance monitor the broker's share of commissions against execution quality. If the broker continues to link allocation to order flow, escalate and consider restricting the relationship.